pittsburgh compound b
Small moleculeexperimentalImaging agent
Pittsburgh compound B (PiB) is a radioactive analog of thioflavin T, which can be used in positron emission tomography scans to image beta-amyloid plaques in neuronal tissue. Due to this property, Pittsburgh compound B may be used in investigational studies of Alzheimer's disease. — Wikipedia
Clinical trial activity
24 trials · 21 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
10
Phase 3
4
Phase 4
1
Earliest trial started Apr 1, 2008 (NCT00950430)
Timeline
Indications
Approved for
Studied for
- Alcoholism · Early Phase 1
- Alzheimer Disease · Phase 4
- Aphasia · Phase 1
- Aphasia, Primary Progressive · Phase 1
- Atherosclerosis · Phase 2
- Atrophy · Phase 1
- Brain Concussion · Phase 1
- Breast Neoplasms · Phase 1
- Cerebral Amyloid Angiopathy · Phase 3
- Cerebral Hemorrhage · Phase 3
- Cognition Disorders · Phase 3
- Cognitive Dysfunction · Phase 2
- Dementia · Phase 1
- Dementia, Vascular · Phase 4
- Demyelinating Diseases · Phase 2
- Frontotemporal Dementia · Phase 4
- Intracranial Hemorrhages · Phase 3
- Lewy Body Disease · Phase 4
- Multiple Sclerosis · Phase 2
- Ovarian Neoplasms · Phase 1
- Parkinson Disease · Phase 2
- Primary Progressive Nonfluent Aphasia · Phase 1
- Speech Disorders · Phase 1
- Spinal Cord Injuries · Phase 1
- Vascular Diseases · Phase 2
Mechanism of action
- Beta amyloid A4 proteinBINDING AGENT
APP binding agent
Chemistry & pharmacology
Loading structure…
SMILES
[11CH3]Nc1ccc(-c2nc3ccc(O)cc3s2)cc1- Mol. weight
- 255.33 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Imaging
- 11-carbon
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPittsburgh compound B ↗
- ChEMBLCHEMBL93124 ↗
- ChEMBLCHEMBL207456 ↗
Also known as
- (11c)6-oh-bta-1
- 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole
- 6-oh-bta-1
- c-11 pib
- c11 pib
- n-methyl-(11c)2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole
- pittsburgh compound b
- pittsburgh compound b
- pittsburgh compound b
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06999434 | Phase 1 | May 5, 2025 | National Institute on Aging (NIA), National Institutes of Health (NIH), Yale University |
| NCT05805839 | Phase 2 | Jul 10, 2023 | Mayo Clinic |
| NCT05361382 | Phase 1 | Nov 23, 2021 | National Institute on Aging (NIA), University of Pittsburgh |
| NCT04542603 | Phase 1 | Aug 31, 2021 | University of Alabama, Birmingham |
| NCT04604587 | Phase 3 | Oct 8, 2020 | National Taiwan University |
| NCT04604600 | Phase 3 | Sep 3, 2020 | National Taiwan University |
| NCT04364672 | Phase 1 | Jul 1, 2020 | University of Alabama, Birmingham |
| NCT04768101 | Early Phase 1 (Phase 1) | Apr 15, 2020 | Vanderbilt University |
| NCT04263337 | Phase 1 | Mar 12, 2020 | Harvard University, Medical College of Wisconsin, University of North Carolina at Chapel Hill |
| NCT04134923 | Phase 2 | Oct 7, 2019 | Washington University in St. Louis |
| NCT03757910 | Early Phase 1 (Phase 1) | Jul 31, 2019 | Columbia University, George Washington University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Yeshiva University |
| NCT03958630 | Phase 1 | Jul 5, 2019 | National Institute of Mental Health (NIMH) |
| NCT03981380 | Phase 2 | Jun 30, 2019 | Columbia University, National Institute on Aging (NIA), Wake Forest University |
| NCT03746366 | Early Phase 1 (Phase 1) | Dec 1, 2018 | National Institute on Alcohol Abuse and Alcoholism (NIAAA), University of Pittsburgh |
| NCT03969732 | Phase 3 | Sep 27, 2018 | National Taiwan University |
| NCT03503331 | Phase 2 | Apr 20, 2018 | University of Alabama, Birmingham |
| NCT03555292 | Phase 2 | Jul 12, 2017 | Oriental Neurosurgery Evidence-Based-Study Team, Tianjin Medical University |
| NCT02740634 | N/A | May 1, 2016 | Mayo Clinic |
| NCT03542656 | Phase 3 | Sep 11, 2014 | National Taiwan University |
| NCT01723553 | Phase 1 | Nov 1, 2012 | Mayo Clinic |
Showing 20 of 24 trials
Page 1 / 2
Organizations
Research & Development (21)
21 organizations
Page 1 / 2